


California Biomedical Industry

2010 Report



Letter from the Governor	1
Letter to Our Stakeholders	2
Defining the California Biomedical Industry	4
Employment	6
Investment	14
Product Development	24
Special Section: Rare Diseases	53
Special Section: Los Angeles and Ventura Counties	58
Academic Research	81
Stem Cell Update	95
Conclusion	98
Methodology	100

NIH Grants

Data

Data for this analysis come from the National Institutes of Health Office of Extramural Research, available at <http://grants.nih.gov/grants/oeer.htm>. The 2008 data do not include research and development contracts due to the unavailability of that data at the time of publication of this report. Prior year's data may also not include research and development contracts to ensure comparability across years. The data include all awards to California from NIH, some of which do not necessarily fund basic biomedical research. For example, some grants were used for training programs and projects that are designed to support the research training of scientists for careers in the biomedical and behavioral sciences, as well as to help professional schools to establish, expand, or improve programs of continuing professional education. Other grants were used to fund health policy or behavioral science research. Despite these caveats, overall the NIH grant funding demonstrates the federal commitment to health science research in California. The 2008 data reflected in this report were collected in the fall of 2009. Data for prior years are from the California Biomedical Industry 2009 Report in order to ensure comparability between reports.

The data come in two forms:

1. State and Congressional District: http://report.nih.gov/award/trends/State_Congressional/StateOverview.cfm
2. NIH SBIR and STTR grants: http://grants.nih.gov/grants/Funding/award_data.htm

Product Development

IMS Research Methodology

IMS experts reviewed the IMS Company Profiles database to focus on companies headquartered in or with significant presence in California, and then linked that information to the IMS R&D Focus database to look at products in development.

R&D Focus covers aspects of global pharmaceutical and biotechnology product development, from discovery stage research to availability on the market. Products including small molecules, monoclonal antibodies, proteins, gene therapies, vaccines and immunotherapies, as well as fixed combination products, biosimilars, *in vivo* imaging agents/diagnostics are included in the scope of the database. Also covered are compounds in specialized delivery systems, targets for use in drug discovery and research collaborations/discovery programs. Drug design technologies and drug delivery systems are included if they are available for partnering.

The main source of information for R&D Focus are company press releases, company interviews and Web sites, scientific conferences (e.g., ASCO, AACR), academic institutes and universities (including technology transfer offices) and company meetings/R&D days.

The California Healthcare Institute

The California Healthcare Institute is a non-profit public policy research organization for California's biomedical R&D industry. CHI represents more than 250 leading medical device, biotechnology, diagnostics and pharmaceutical companies and public and private academic biomedical research organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery.

California Healthcare Institute
1020 Prospect Street, Suite 310
La Jolla, CA 92037
Phone: (858) 551-6677
Fax: (858) 551-6688
www.chi.org

PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group

PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group (www.pwc.com/pharma or www.pwc.com/medtech) provides assurance, tax and advisory services to proprietary, generic and specialty drug manufacturers, medical device and instrumentation suppliers, biotechnology companies, wholesalers, pharmacy benefit managers, contract research organizations, and industry associations. The firm is dedicated to delivering effective solutions to the complex strategic, operational, and financial challenges facing pharmaceutical, biotechnology and medical device companies. More than 163,000 people in 151 countries across our network share their thinking, experience, and solutions to develop fresh perspectives and practical advice.

Tracy Lefteroff, Partner
PricewaterhouseCoopers LLP
10 Almaden Blvd., Suite 1600
San Jose, CA 95113
Phone: (408) 817-3700
Fax: (408) 827-5050

Attila Karacsony, Director
PricewaterhouseCoopers LLP
400 Campus Drive
Florham Park, NJ 07932
Phone: (973) 236-5640
Fax: (813) 329-0200

Report Authors

David L. Gollaheer, Ph.D.
President and CEO
California Healthcare Institute

Tracy T. Lefteroff
National Life Sciences Partner
PricewaterhouseCoopers LLP

Project Team

Nicole Beckstrand
California Healthcare Institute

Sarah Thailing
California Healthcare Institute

Molly Ingraham
California Healthcare Institute

Lambert Shiu
PricewaterhouseCoopers LLP

Writing

Christi Whittemore
Stellar Road Copy Works

Economic Analysis

Jack Rodgers, Ph.D.
PricewaterhouseCoopers LLP

Kristen Soderberg
PricewaterhouseCoopers LLP

Research

Tiffany Taluban
California Healthcare Institute

Holly Frisque
California Healthcare Institute

Ann Clawson
California Healthcare Institute